Search results
'Impressive' New Data on Novel Schizophrenia Hopeful KarXT
Medscape· 4 days agoThe novel investigational antipsychotic KarXT was effective and well tolerated in adults with ...
UPDATE 1-Teva and Medincell's schizophrenia drug meets main goal of late-stage study
Reuters via Yahoo Finance· 4 days agoSymptoms for schizophrenia include delusions, hallucinations, disorganized speech, trouble with thinking and lack of motivation. (Reporting by Puyaan Singh ...
NeuShen begins dosing for Phase I trial of schizophrenia treatment
Clinical Trials Arena via Yahoo Finance· 3 days agoPAM has the potential to treat psychosis in Alzheimer's or Parkinson's disease. Developed from...
Attorney for Doctor Who Drove Wife, Kids Off Cliff Says He's a 'Good Man' as Defense Seeks Mental...
People via Yahoo News· 17 hours agoShe cited testimony from Dr. Yan Chan and said Patel was diagnosed with schizoaffective disorder,...
Teva and Medincell report positive data for TEV-‘749 in schizophrenia trial
Clinical Trials Arena via Yahoo Finance· 3 days agoThe Phase III SOLARIS trial has revealed promising results for TEV-‘749, which Teva...acting...
Teva, Medincell's schizophrenia drug succeeds in late-stage study
Reuters via Yahoo News· 4 days agoU.S.-listed shares of Teva were up 3.3% at $14.41 in premarket trading. The companies hope that the...
TEVA Q1 Earnings Miss, Schizophrenia Study Meets Goal, Stock Up
Zacks via Yahoo Finance· 3 days agoTEVA reports mixed first-quarter results, missing estimates for earnings but beating the same for...
...olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with Schizophrenia -...
Benzinga· 4 days agoThe study met its primary endpoint achieving clinically meaningful and statistically significant reductions across all TEV-‘749 dose groups versus placebo in the Positive and Negative Syndrome Scale (PANSS) total
Teva Stock Powers Ahead as Schizophrenia News Offsets Mixed Earnings
Barrons.com· 4 days agoShares of Teva Pharmaceutical Industries were climbing yet again on Wednesday, after the company...
...First-in-Human Trial of NS-136, a Novel Selective M4 Receptor Positive Allosteric Modulator for...
NBC 17 Raleigh· 4 days agoM4 PAM presents a novel approach to treating schizophrenia, with potential benefits in alleviating negative symptoms and cognitive impairment.